We co-expressed Kaposi's sarcoma-associated herpesvirus G protein-coupled receptors (KSHV-GPCRs) with thyrotropin-releasing hormone (TRH) receptors or m1-muscariniccholinergic receptors in Xenopus oocytes and in mammalian cells. In oocytes, KSHV-GPCR expression resulted in pronounced (81%) 
Introduction

KSHV-GPCR
1 , the gene product of 0RF74 in the KSHV (human herpesvirus 8) genome, is a GPCR homologous to h uman chemokine CXC receptor 2 (1, 2) . Our group demonstrated that rodent fibroblasts expressing KSHV-GPCRs formed tumors in mice (3) .
Recently, transgenic mice in which the KSHV-GPCR gene was regulated by the human CD2 enhancer/promoter and locus control region were shown to develop angioproliferative lesions that resembled the lesions of KS (4) . These reports make the mechanism of action of KSHV-GPCR interesting in terms of tumorigenesis. We reported that KSHV-GPCR exhibited marked constitutive, agonist-independent activity in mammalian cells (2) . We also demonstrated that the constitutive activity of the viral GPCR could be inhibited by IP10, acting as an inverse agonist (5) . These results were later confirmed by Rosenkilde et al. (6) . Lastly, we showed that signaling by KSHV-GPCR could be inhibited by GPCRspecific protein kinases and suggested that this may represent a form of homologous desensitization of this viral receptor (7) . However, the effect of the constitutive activity of KSHV-GPCR on signaling by other receptors (heterologous desensitization) has not been previously investigated
To investigate the effect of constitutive signaling by KSHV-GPCR on other receptors that utilize the phosphoinositide/calcium signaling pathway, we studied the behavior of this 1 The abbreviations used are: KSHV-GPCR, Kaposi's sarcoma-associated herpesvirus G proteincoupled receptor; IP-10, interferon-γ-inducible protein 10; TRH, thyrotropin-releasing hormone;
TRH-R, TRH receptor; m1-R, m1-muscarinic-cholinergic receptor; InsP 3 , inositol 1,4,5-trisphosphate; GFP, green fluorescent protein; ACh, acetylcholine; Groα, growth-related oncogene α; GRP, gastrin-releasing peptide; [Ca 
Experimental procedures
Xenopus laevis oocytes Defolliculated oocytes were obtained from mature Xenopus females, essentially as previously described (8) . In vitro-transcribed cRNAs for WT TRH-Rs, m1-Rs (1 ng/oocyte), gastrin-releasing peptide receptors (GRP-Rs, 0.23 ng/oocyte) and KSHVGPCRs (1-3 ng/oocyte) were injected 48 h before the assay as described previously (9) (10) (11) .
Electrophysiology Two-electrode voltage clamp measurements were performed at V H = -80 mV, as previously described (10, 12) . Chloride currents were continuously recorded. Intracellular injections of InsP 3 were performed using a Drummond microinjector (volume 4.6-9.2 nl/oocyte) as previously described (13 corresponding R min and R max as previously described (15) . Individual vials (50 µg) of the acetoxymethyl derivative of fura-2 were stored dry at 0 o C and reconstituted in dimethyl sulfoxide, at a concentration of 1 mM, for each experiment. The basic components of the experimental apparatus have been described previously (15, 19) . Briefly, the imaging workstation was controlled with the Metafluor software package (Universal Imaging, Westchester, PA).
Image pairs were obtained every 0. ND96 solution was used in all short-term incubations and NDE for culturing of oocytes (21) .
Statistics
All experiments were performed on a large number of oocytes (n) from a number of donors (N). In calcium imaging experiments, several coverslips were assayed for each condition (N) and the number of cells was denoted by n . Results were presented as mean±SE. All results were analyzed by unpaired Student's t-test with p<0.05 considered as significant difference between two populations.
Results
Expression of KSHV-GPCRs in
Xenopus oocytes did not affect whole cell chloride currents or membrane potential in the absence of agonist. Moreover, there was no current response when the oocytes were exposed to several chemokine agonists (data not shown).
However, expression of KSHV-GPCRs caused marked inhibition of Ca
2+
-activated chloride current responses to the cognate agonists of other co-expressed GPCRs. When 1-3 ng of KSHV-GPCR were injected, the response to 1 µM TRH was inhibited from 2980±148 to 576±168 nA (81% inhibition, n=145, N=14), the response to 10 µM ACh (Fig. 6 ).
Oocytes expressing KSHV-GPCR responded t o a challenge with the cytokine agonist
Groα by a slow increase in 45 Ca 2+ efflux. By 20 min of exposure to 1µM of GROα, the fractional rate of efflux reached 1.14±0.14, while the basal rate was 0.6±0.06 % of residual label/min (n=18-19, N=3). min incubation with 10 µM TRH was 31±5% of total label, co-expression of KSHVGPCRs resulted in an efflux of 12±4%, i.e. 61% inhibition of the TRH response (Fig. 7) .
This was also true for the initial phase of efflux within the first min (data not shown), which is more directly related to the rapid, transient electrophysiological response to TRH.
To investigate the mechanism of heterologous inhibition of TRH-R and m1-R-mediated responses, we studied the effect of KSHV-GPCR expression on lnsP 3 -evoked IP-10 partially reversed the inhibition of responses to microinjected lnsP 3 (Fig. 8A) .
Incubation of oocytes co-expressing TRH-Rs and KSHV-GPCRs with 1 µM IP-10 for 30
to 60 min increased the response to InsP 3 from 26 to 51% of control. The time course of the action of IP-10 on lnsP 3 -evoked responses (Fig. 8B ) was similar to that on the TRH response (see Fig. 4 ) and on the enhanced efflux of 45 Ca 2 + (Fig. 6 ).
To test the hypothesis that the constitutive signaling of KSHV-GPCR causes depletion of the calcium pool, we used thapsigargin, which inhibits the endoplasmic reticulum calcium ATPase and, consequently, empties the pool. Oocytes labeled with 45 Ca 2+ were exposed to 2 µM thapsigargin. In control oocytes, the basal efflux was low, resulting in a cumulative loss of 16.6±1.0% of total radiolabel at 150 min of incubation. Addition of thapsigargin at 30 min resulted in a major increase in efflux, leading to a loss of 83.5±2.0%
of total radiolabel. In contrast, oocytes expressing KSHV-GPCR exhibited a much higher efflux (loss of 75.0±3.1% of total radiolabel at 150 min of incubation). Treatment with thapsigargin led to a small, statistically insignificant increase of cumulative efflux. After 120 min with thapsigargin the KSHV-GPCR expressing oocytes lost 76.0±3.1% of total label. These results are shown in Fig. 9A . The effect of KSHV-GPCR's constitutive signaling on calcium pools was more apparent when fractional efflux rates were calculated (Fig. 9B) . Before the addition of thapsigargin, basal fractional efflux rates were 0.17±0.03 and 0.76±0.07% of residual label/min for control or KSHV-GPCR-expressing oocytes, respectively. Upon addition of thapsigargin, the fractional efflux rate in control oocytes increased rapidly, to 1.43±0.16% of residual label/min 30 min after the addition of the drug. Thereafter, the rate decreased slightly till the end of the incubation. In oocytes expressing KSHV-GPCRs, 20 min of incubation with thapsigargin accelerated the fractional efflux rate to a maximum of 1.84±0.24% of residual label/min. Further incubation with thapsigargin led to a major decrease in fractional efflux rate, indicating that the depleted pools could not support the high rate of efflux.
Discussion
We previously showed that a constitutively signaling T RH-R mutant caused homologous (of TRH-R itself) and heterologous (of other co-expressed GPCRs) desensitization in Xenopus oocytes (11, 14) . This desensitization was partially or fully abolished by short-term incubation with chlordiazepoxide, an inverse agonist of TRH-R. The findings presented here, together with our previous findings concerning a constitutively active TRH-R mutant (11, 14, 23) were assayed for responses to 1 µM TRH. Representative experiment (n=15) is shown. Results are presented as fractional efflux rates. Each point represents the mean±SE of 8 oocytes. 
KSHV-GPCR is
